PVLA Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. (PVLA) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $1.63 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +15.4% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Palvella Therapeutics, Inc.
Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies.
Sector
Healthcare
Industry
Biotechnology